Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $181.3M
- Enterprise value
- $181.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $3.60
- 52-wk low
- $0.99
- Beta
- —
- Shares out
- 72.2M
5-year trend
What this company does
Acumen Pharmaceuticals is a clinical-stage biotech developing antibody therapies for Alzheimer's disease that target soluble amyloid-beta oligomers, a toxin believed to drive the disease. The company generates no product revenue and funds operations through capital markets while advancing its lead candidate sabirnetug. Its pivotal moment hinges on the Phase 2 ALTITUDE-AD trial of sabirnetug, with top-line readout expected in late 2026 against a competitive field that includes approved drugs Leqembi and donanemab.
Generated from ABOS's filing dated 2026-03-26
Key risks
- Binary catalyst risk: ALTITUDE-AD Phase 2 top-line results not expected until late 2026; sabirnetug is Acumen's sole clinical asset.
- ARIA-E safety signal: 21% incidence at 60 mg/kg in Phase 1; ALTITUDE-AD doses 35/50 mg/kg may carry similar risk.
- Competitive pressure: FDA-approved Leqembi (2023) and donanemab (2024) already entrenched in anti-amyloid AD market before sabirnetug readout.
Generated from ABOS's filing dated 2026-03-26
Profitability
Return on equity
-172.3%
206.1%Return on assets
-98.8%
130.7%Leverage
Debt / equity
0.74×
136.6%Long-term debt / equity
0.32×
96.5%Debt / assets
42.7%
78.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-20.7M | +28.0% | — |
Q4 2025 2025-12-31 | — | — | $-25.1M | +32.3% | — |
Q3 2025 2025-09-30 | — | — | $-26.5M | +11.1% | — |
Q2 2025 2025-06-30 | — | — | $-41.0M | -99.4% | — |
Q1 2025 2025-03-31 | — | — | $-28.8M | -93.6% | — |
Q4 2024 2024-12-31 | — | — | $-37.2M | — | — |
Q3 2024 2024-09-30 | — | — | $-29.8M | -129.7% | — |
Q2 2024 2024-06-30 | — | — | $-20.5M | -76.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ABOS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$535.9K
Net activity
−$535.9K
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ABOS
Institutional value
$24.6M
Total shares held
11.3M
Distinct holders
38
-33 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Sands Capital Ventures, LLC | 3.7M | $8.8M | +303.0K (+8.9%) | Added |
| 2 | FRANKLIN RESOURCES INC | 2.3M | $5.4M | +0 (+0.0%) | No change |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $3.6M | — | New |
| 4 | Hudson Bay Capital Management LP | 968.9K | $2.3M | +243.9K (+33.6%) | Added |
| 5 | Pathstone Holdings, LLC | 859.1K | $2.0M | +0 (+0.0%) | No change |
| 6 | VANGUARD FIDUCIARY TRUST CO | 199.2K | $470.2K | — | New |
| 7 | BlackRock, Inc. | 178.3K | $420.8K | +8.8K (+5.2%) | Added |
| 8 | DIMENSIONAL FUND ADVISORS LP | 119.8K | $281.8K | +70.7K (+144.1%) | Added |
| 9 | CATALYST FINANCIAL PARTNERS LLC | 89.7K | $211.7K | +0 (+0.0%) | No change |
| 10 | JANE STREET GROUP, LLC | 89.7K | $211.6K | -52.5K (-36.9%) | Trimmed |
| 11 | PFG Investments, LLC | 80.8K | $190.8K | +61.9K (+325.5%) | Added |
| 12 | Prospera Financial Services Inc | 50.0K | $118.0K | +0 (+0.0%) | No change |
| 13 | Catalyst Funds Management Pty Ltd | 45.6K | $107.6K | +16.0K (+54.1%) | Added |
| 14 | UBS Group AG | 37.1K | $87.7K | +15.6K (+72.3%) | Added |
| 15 | Intrepid Financial Planning Group LLC | 30.1K | $71.2K | +0 (+0.0%) | No change |
| 16 | AXQ CAPITAL, LP | 28.5K | $67.2K | — | New |
| 17 | Independent Advisor Alliance | 19.0K | $44.8K | +0 (+0.0%) | No change |
| 18 | PINNACLE ASSOCIATES LTD | 18.0K | $42.5K | +0 (+0.0%) | No change |
| 19 | Pinnacle Wealth Management Advisory Group, LLC | 18.0K | $42.5K | +0 (+0.0%) | No change |
| 20 | CLUNE & ASSOCIATES, LTD. | 16.5K | $38.9K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With ALTITUDE-AD topline not until late 2026, what is your current cash runway and how do you bridge funding without a dilutive raise?
- 2
INTERCEPT-AD showed 21% ARIA-E at 60mg/kg; why should investors be confident the 50mg/kg ALTITUDE arm won't trigger similar tolerability concerns versus Leqembi?
- 3
The JCR deal carries up to $555M in milestones plus a mid-2027 IND; how do you justify EBD spend while sabirnetug remains unproven in Phase 2?
Refreshed when ABOS files a new report · last from 2026-03-26